1. Proglumide as a Morphine Adjunct in Cancer Pain Management
Zale P. Bernstein, MD, Steven Yucht, MD, Ellen Battista, RN, MS, Mark Lema, MD, PhD, Monica B. Spaulding, MD 
Journal of Pain and Symptom Management 
Volume 15, Issue 5, Pages (May 1998)
DOI: /S (98)

2. Fig. 1.
Schema of proglumide study. *Indicates first scheduled analgesic post 6 a.m. and 12 noon, respectively
Journal of Pain and Symptom Management  , DOI: ( /S (98) )

3. Fig. 2.
Visual analog scale; one of five visual analog scale descriptors used—please see text
Journal of Pain and Symptom Management  , DOI: ( /S (98) )

4. Fig. 3.
Visual analogue scale pain descriptors—results of treatment arms and baseline for time of day and post-treatment testing times. PRO, one-half usual analgesic dose plus Proglumide; PLA, full usual analgesic dose plus placebo; and BAS, baseline (full) analgesic dose prior to study, respectively. *Significant differences between treatment arms, all other responses statistically equivalent for all other descriptors
Journal of Pain and Symptom Management  , DOI: ( /S (98) )

5. Fig. 4.
Tursky verbal rating scale descriptors—results of treatment arms and baseline for times of day and post-treatment testing times. PRO, PLA, and BAS refer to one-half usual analgesic dose plus Proglumide, full usual analgesic dose plus placebo and baseline (full) analgesic dose prior to study, respectively. All responses statistically equivalent for all descriptors. For derivation of mean verbal scores, see text
Journal of Pain and Symptom Management  , DOI: ( /S (98) )